EHMT2 and cancer: Because YM155, an interleukin enhancer-binding factor 3 (ILF3) inhibitor [19], can block EGFR autophosphorylation to inhibit G9a-mediated stemness [18], EGFR downstream of G9a may also regulate cancer stemness and HER3 expression.